Author Archives: Millie Nelson

iBio to divest CDMO biz and lose 60% of its workforce

iBio is looking to divest its CDMO services in order to transform into an antibody discovery and development firm. Artificial intelligence (AI) precision antibody firm iBio has said that it is seeking to divest its contract development and manufacturing organization (CDMO) so it can restructure into an antibody discovery and development company, which will result in 50% annualized cost savings. On the back of this transition, the firm hopes to invest in a pipeline of immune-oncology assets and an AI-based…

Feeling the cold: Envirotainer expansion to surpass a billion doses annually

Envirotainer says it has invested heavily to expand capacity and surpass a billion doses per year to meet future demand for temperature-controlled shipping at its Stockholm, Sweden plant. Envirotainer, a cold chain solution provider for the shipment of pharmaceuticals, has not disclosed specifical financial details of the expansion but said it has “invested heavily” at its production site in Rosersberg, north of Stockholm to up capacity to meet future need for temperature-controlled shipping. The company says the decision to expand…

Charles River ups cell therapy production with Memphis expansion

Charles River Laboratories says it will expand its cell therapy facility in Memphis, Tennessee to enable clients to streamline and accelerate their programs. Contract development manufacturing organization (CDMO) Charles River will increase its existing 16 cleanrooms by adding nine processing suites at its Memphis plant. The company says that the facility expansion will support its cell therapy clients and help them to speed their programs to commercialization. According to the firm, the suites will include advanced cleanroom facility technology and…

GEA breaks ground on $20m+ site in Wisconsin

GEA has started construction of its repair, logistics, assembly, production, and training facility located in Janesville, Wisconsin. According to the firm, the 85,000 square-foot building – which is GEA’s first greenfield site in North America in 50 years – aims to bring the company closer to its Midwest customer base and service their industry needs. “The Janesville facility will bring us closer to our growing Midwest customer base and it will enable us to meet the growing demand for our…

ten23 looks to on-body-injectors to reduce healthcare costs

CDMO ten23 health is supporting customers to develop an on-body-injector platform, which it says could lower overall treatment costs. Ten23, a contract development manufacturing organization (CDMO) focused on developing and commercializing injectable biopharmaceuticals met BioProcess Insider at CPHI, Frankfurt to discuss its on-body-injector activity. “Instead of holding and keeping in position a syringe for the time of injection, on-body-injectors are stuck to the body,” explained Michael Petersen, ten23’s chief commercial officer. “A button is pressed, and a small motor is…

ReiThera opens Italy viral vector production plant

ReiThera has expanded its large-scale viral vector manufacturing capabilities at its Castel Romano Technopole plant through receiving operational authorization from the Italian Medicines Agency. According to the contract development manufacturing organization (CDMO), the recently opened 1,500 square meter facility located close to Rome will have production scales of up to 3,000 L and produce viral vectors for vaccines and gene therapies. “Thanks to the operational authorization of this expanded facility, the ReiThera team, which combines high-level scientific knowledge with extensive…

CSL Seqirus to access Arcturus’ sa-mRNA vax tech

Through the collaboration and license agreement, CSL Seqirus will access Arcturus Therapeutics’ late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology.  Arcturus will grant CSL Seqirus (part of CSL Limited) a license to its sa-mRNA technology in order to support the research, development, production, and commercialization of vaccines for SARS-CoV-2, as well as influenza, pandemic preparedness, and a further three global respiratory infectious diseases. “This collaboration on next generation mRNA is another example of CSL’s relentless pursuit of disruptive innovation when public…

Cell line platform reduces timelines by 33%, says Aragen

Aragen Life Sciences has launched its RapTr 2022 cell line development platform, which it says offers reduced timelines and delivers increased titres. Contract development manufacturing organization (CDMO) Aragen has launched its optimized RapTr 2022 cell line development (CLD) platform. BioProcess Insider spoke to the firm’s chief commercial officer, Ramesh Subramanian, at CPHI, Frankfurt who told us that RapTr stands for “rapid titers.” “We provide solutions to the customer and titres are important because the more protein you can make equals…

Vetter Pharma ups storage capacity with warehouse expansion

Vetter Pharma has completed its €20 million ($19 million) warehouse expansion, which it says will help meet customer supply demands. Contract development manufacturing organization (CDMO) Vetter says that the fully automated building located in Ravensburg, Germany optimizes the firm’s logistical infrastructure by providing storage space for materials it considers having high-stock turnover rates, such as packaging components. The firm claims that construction of the warehouse, which began in April 2021, will mean that “valuable capacity” is freed up in the…

Fill-finish roundup: News from INCOG, Recipharm, WuXi Bio

INCOG BioPharma completes installation of a filling line in Indiana, Recipharm invests in Lab+ filling technology in France, and WuXi Biologics expands its fill-finish capacity and capability in China. Welcome to our fill-finish roundup. First up is contract development manufacturing organization (CDMO) INCOG, which specializes in sterile injectables. The firm has completed the installation of its OPTIMA multi-use production filling line at its Fishers, Indiana plant. “The OPTIMA multi-use line serves as our highly customized, injectable therapy ‘bottling line’ at…